Abstract. Stanniocalcin-1 (STC-1), a secreted glycoprotein, is highly expressed in a variety of human malignancies. However, the role of STC-1 has not been fully elucidated in breast cancer cells. Here, we investigated whether STC-1 acts as a prognostic factor in triple-negative breast cancer (TNBC) patients, and we explored the cellular mechanism in breast cancer cells. The level of STC-1 expression was directly associated with the relapse-free and overall survival of basal-type breast cancer patients. Breast cancer patients with a high level of STC-1 had poor prognosis. In addition, our results showed that the level of STC-1 expression was markedly higher in TNBC than in non-TNBC cells. Invasiveness of the TNBC cells was also significantly increased in response to recombinant human STC-1 treatment. In contrast, the invaded cell numbers were completely decreased by STC-1 siRNA overexpression in the Hs578T and MDA-MB-231 TNBC cells. Our results showed that the phosphorylation of c-Jun N-terminal protein kinase (JNK) and c-Jun was increased after STC-1 treatment but not the phosphorylation of ERK and p38 MAPKs in the Hs578T and MDA-MB-231 TNBC cells. Furthermore, expression of one invasion-related gene MMP-9, was increased by STC-1 treatment. STC-1-induced MMP-9 expression was suppressed by SP600125 (a JNK inhibitor) in the Hs578T cells. STC-1-induced cell invasiveness was also inhibited by SP600125. Taken together, we demonstrated that aberrant STC-1 expression is associated with poor prognosis and stimulates the invasiveness of TNBC cells through the JNK/c-Jun-dependent signaling pathway.
Introduction
Breast cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer among women and the incidence rate is higher in young women in comparison to older ones (1, 2) . One breast cancer subtype, triple-negative breast cancer (TNBC) accounts for ~15-20% of breast cancer cases and occurs more commonly in younger women (3, 4) . TNBCs are highly aggressive and often have a poor prognosis when compared to other breast cancer subtypes, including luminal and HER2-type breast cancers (5, 6) . Due to the lack of ER, PR, and HER2 expression, TNBCs are insensitive to anti-hormonal and HER2-targeted therapies (7) . Although sensitive to chemotherapy, TNBCs have an intrinsic aggressive clinical course associated with high proliferation, high histologic grade, earlier time to recurrence, and higher risk of distant recurrence (5) . Thus, many researchers have attempted to discover promising therapeutic targets for the treatment of TNBC breast cancer patients.
Stanniocalcins (STCs) are secreted glycoprotein hormones and are involved in calcium/phosphate homeostasis and cell development (8, 9) . STCs consist of STC-1 and -2 and are broadly expressed in multiple mammalian tissues including the ovary, prostate, and kidney (8, 10, 11) . In particular, STC-1, a 56-kDa homodimeric glycoprotein hormone, is highly expressed in a variety of cancers such as breast, ovarian, and colorectal cancers (12) (13) (14) (15) . STC-1 is involved in various biological events such as cell proliferation, apoptosis, and inflammation (14, 16) . Furthermore, STC-1 triggers tumor angiogenesis via upregulation of vascular endothelial growth factor (VEGF) in gastric cancer cells (17) . Abnormal STC-1 expression is generally correlated with tumorigenesis and poor clinical outcomes in ovarian and colorectal cancers (10, 14, 18) . However, little is understood about the clinical significance of STC-1 expression and the intracellular signaling events in breast cancer.
Ninety percent of all cancer-related deaths are caused by tumor metastasis. Metastasis is a process which includes excessive tumor cell proliferation, degradation of the surrounding stroma microenvironment [extracellular matrix (ECM)], migration, and invasion (19, 20) . In this multiple-step process, the biological activity of matrix metalloproteinases (MMPs), a large family of ECM-degrading enzymes, facilitates tumor cell growth, migration, and angiogenesis through cleavage of ECM components (21) . The expression of MMPs in tumors is primarily regulated at the transcriptional level in response to growth factors and cytokines (22, 23) . Enhancement of MMP-1 expression by TNF-α is mediated by coordinate activation of c-Jun N-terminal protein kinase (JNK) and p38 MAPK pathways (24) . In particular, the JNK/c-Jun signaling pathway accelerates cell migration and invasion and promotes metastasis in breast cancer cells (25) (26) (27) (28) . In contrast, Fyn-related kinase (FRK) was found to reduce cell migration and invasion via inhibiting the JNK/c-Jun signaling pathway in glioma cells (28) .
The aim of this study was to investigate the clinical significance of STC-1 in basal-type breast cancer as well as the regulatory mechanism of STC-1-induced cell invasion. Consequentially, elevated STC-1 expression was associated with poor prognosis in basal-type breast cancer patients. The levels of STC-1 mRNA and protein expression were also significantly increased in the TNBC cells. Furthermore, recombinant human STC-1 treatment augmented the invasiveness of the TNBC cells while STC-1 siRNA overexpression suppressed the invasiveness of the TNBC cells. In addition, we found for the first time that STC-1 upregulated MMP-9 expression through the JNK/c-Jun-dependent signaling pathway. STC-1-induced MMP-9 expression was associated with the invasiveness of the TNBC cells. Therefore, we demonstrated that aberrant STC-1 expression enhanced the invasiveness of the TNBC cells through JNK/c-Jun-dependent MMP-9 induction. STC-1 may be a promising therapeutic target for the treatment of TNBC patients.
Materials and methods
Reagents. Cell culture media and antibiotics were purchased from Life Technologies (Rockville, MD, uSA). Fetal bovine serum (FBS) was purchased from Hyclone (Logan, uT, uSA). Anti-phospho-JNK, c-Jun, ERK, p38, and STC-1 antibodies were purchased from Epitomics (Burlingame, CA, uSA). Anti-total-JNK, ERK, p38, and β-actin antibodies were purchased from AbFrontier (Seoul, Korea). Secondary horseradish peroxidase (HRP)-conjugated antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, uSA). Recombinant human STC-1 was purchased from ProSpec (ProSpec HOR-259; Israel). SP600125 was purchased from Calbiochem (San Diego, CA, uSA).
Cell cultures and drug treatment. MCF7, Hs578T, MDA-MB-231, and MDA-MB-468 breast cancer cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 100 Iu/ml penicillin, and 100 µg/ml streptomycin. BT474 and SKBR3 breast cancer cells were cultured in RPMI-1640 supplemented with 10% FBS, 100 Iu/ml penicillin, and 100 µg/ml streptomycin. Cells were grown in a humidified atmosphere with 5% CO 2 at 37˚C. In the drug treatment experiment, after serum starvation for 24 h, the cells were pre-treated with SP600125 for 1 h, and then treated with recombinant human STC-1 for 24 h.
Analysis of public database. Expression data were downloaded from a public database [Kaplan-Meier plotter database (http://kmplot.com/breast)]. The clinical value of STC-1 was analyzed by Kaplan-Meier survival plots in basal-type breast cancer patients. The hazard ratio with 95% confidence intervals and log-rank P-values were calculated.
Real-time polymerase chain reaction (PCR).
Total RNA was extracted from the cells using TRIzol reagent (Invitrogen, Carlsbad, CA, uSA), according to the manufacturer's protocol. Isolated RNA samples were then used for RT-PCR. Samples of total RNA (1 µg) were reverse-transcribed into cDNA in 20-µl reaction volumes using a first-strand cDNA synthesis kit for RT-PCR, according to the manufacturer's instructions (MBI Fermentas, Hanover, MD, uSA). Gene expression levels were quantified by real-time PCR using a SensiMix SYBR kit (Bioline, Ltd., London, uK) and 100 ng of cDNA per reaction. The primer sequences used for this analysis were as follows: human STC-1 (forward, 5'-CAC ACC CAC GAG CTG ACT TC-3' and reverse, 5'-TCT CCC TGG TTA TGC ACT CTC-3') and ACTB as an internal control (forward, 5'-TCA CCA TTG GCA ATG AGC GGT T-3' and reverse, 5'-AGT TTC GTG GAT GCC ACA GGA CT-3'). An annealing temperature of 60˚C was used for all of the primers. PCRs were performed in a standard 384-well plate format with an ABI 7900HT real-time PCR detection system (Applied Biosystems, Foster City, CA, uSA). For data analysis, the raw threshold cycle (Ct) value was first normalized to the housekeeping gene for each sample to obtain a ΔCt. The normalized ΔCt was then calibrated to the control cell samples resulting in a ΔΔCt.
Western blotting. Cell lysates were prepared for detection of STC-1, β-actin, anti-total and phospho-JNK, c-Jun, ERK, p38 expression. Equal proteins (50 µg) were boiled for 5 min in Laemmli sample buffer and then electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels. Separated proteins were transferred to polyvinylidene fluoride (PVDF) membranes, and the membranes were blocked with 10% skim milk in Tris-buffered saline (TBS) containing 0.01% Tween-20 (TBST) for 15 min. The blots were washed three times in TBST and then incubated with STC-1, β-actin, anti-total and phospho-JNK, c-Jun, ERK, p38 antibodies in TBST buffer at 4˚C overnight. The blots were washed three times in TBST and subsequently incubated with secondary HRP-conjugated antibodies (1:2,000 dilution) in TBST buffer. After a 1-h incubation at room temperature (RT), the blots were washed three times in TBST. ECL™ Prime reagent (GE Healthcare, Buckinghamshire, uK) was used for development.
Cell invasion assay. Twenty-four-well Boyden chambers with Matrigel-coated filters (8-µm pore size) were purchased from Becton-Dickinson (San Diego, CA, uSA). Hs578T and MDA-MB-231 breast cancer cells transfected with scrambled and STC-1 siRNA were tested for invasion at 48 h. The cells were resuspended in culture media (5x10 4 cells/well) and were seeded into the Matrigel-coated upper compartment of the invasion chambers. Fresh culture media with 5% FBS were added to the lower compartment of the invasion chamber. In addition, Hs578T cells were resuspended in culture media and then seeded into the Matrigel-coated upper compartment of the invasion chambers in the presence or absence of 50 ng/ml STC-1 and/or 10 µM SP600125. Fresh culture media with 5% FBS were added to the lower compartment of the invasion chamber. After 24 h (Hs578T cells) or 48 h (MDA-MB-231 cells) of incubation, the cells on the upper side of the filter were removed using cotton swabs. Invaded cells through the Matrigel were located on the underside of the filter. The underside of the filter was fixed in 100% methanol, washed in 1X PBS, and stained using hematoxylin and eosin (H&E). These cells were analyzed using Aperio ScanScope XT (Aperio Technologies, Vista, CA, uSA).
STC-1 siRNA transfection. Scrambled and STC-1 siRNAs were purchased from Bioneer (Daejeon, Korea). Hs578T and MDA-MB-231 TNBC cells were seeded in a 6-well plate. Cell transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The cells were maintained in culture media without FBS and antibiotics for 24 h while Lipofectamine transfection, and then further incubated in fresh culture media with 10% FBS for 24 h.
Enzyme-linked immunosorbent assay. ELISA assay was performed on culture media (200 µl) collected from Hs578T and MDA-MB-231 TNBC cells. Secreted protein levels of STC-1 were measured using an ELISA kit (R&D Systems, Minneapolis, MN, uSA), according to the manufacturer's instructions. Secreted protein levels were analyzed at a wavelength of 450 nm on a spectrometer (SpectraMax 190; Molecular Devices, Sunnyvale, CA, uSA).
Zymography. Samples (100 µl) were resuspended in loading buffer and run on a 10% SDS-PAGE gel that contained 0.5 mg/ml gelatin without prior denaturation. After electrophoresis, the gels were washed to remove SDS and incubated for 30 min at RT in a renaturing buffer. The gels were incubated for 48 h at 37˚C in a developing buffer. Next, the gels were subsequently stained with Coomassie Brilliant Blue G-250, destained in 30% methanol, and flooded with 10% acetic acid to detect gelatinase secretion.
Statistical analysis. Statistical significance was determined using a Student's t-test. The results are presented as means ± SEM. All quoted P-values were two-tailed and differences were considered statistically significant when P<0.05. Statistical analysis was performed using Microsoft Excel.
Results
Elevated STC-1 expression is associated with poor prognosis in basal-type breast cancer patients. Clinically, to investigate the correlation between STC-1 expression and the prognosis of breast cancer patients, we analyzed the clinical value of STC-1 in breast cancer patients using a Kaplan-Meier plotter database (http://kmplot.com/breast). As shown in Fig. 1A and B, we found that breast cancer patients with a high level of STC-1 presented with poor prognosis. In the basal-type breast cancer patients, patients with high expression of STC-1 showed poorer relapse-free (P=0.044, Fig. 1A ) and overall survival (P=0.0054, Fig. 1B ) than did patients with low expression. However, the level of STC-1 expression did not affect the relapse-free and overall survival of the luminal-and HER2-type breast cancer patients (data not shown). Therefore, we demonstrated that aberrant STC-1 expression is associated with poor clinical outcomes in basal-type breast cancer patients.
The levels of STC-1 expression in breast cancer cells. Next, we measured the levels of STC-1 mRNA and protein expression in various breast cancer cell lines. Our results showed that the levels of STC-1 expression were higher in the TNBC cells than these levels in the non-TNBC cells ( Fig. 2A and B) . The levels of STC-1 mRNA expression were significantly increased in the TNBC cells when compared with levels in the non-TNBC cells (Fig. 2A) . The levels of STC-1 mRNA expression were significantly increased by 103.16±9.51-fold (Hs578T cells), 58.45±1.71-fold (MDA-MB-231 cells), and 27.88±3.94-fold (MDA-MB-468 cells) of the control level (MCF7 cells) (Fig. 2A) . The STC-1 mRNA level of the Hs578T cells was the highest among the TNBC cells ( Fig. 2A) . under the same condition, STC-1 protein levels were also increased in the TNBC cells (Fig. 2B) . Based on these results, we demonstrated that the levels of STC-1 expression were the highest in the TNBC cells among all the breast cancer cell types.
Induction of STC-1 expression enhances the invasiveness of TNBC cells.
To verify the effect of STC-1 on TNBC cells, Hs578T and MDA-MB-231 TNBC cells were treated with 50 ng/ml STC-1 for 24 and 48 h, respectively. As shown in Fig. 3A , recombinant human STC-1 significantly increased the invasiveness of the TNBC cells. The rates of cell invasion in response to STC-1 treatment were increased by 180.38 and 231.53%, compared to the vehicle-treated Hs578T and MDA-MB-231 cells, respectively (Fig. 3A) . In contrast, we investigated whether STC-1 siRNA overexpression suppresses the invasion ability of TNBC cells. Hs578T and MDA-MB-231 cells were transfected with scrambled or STC-1 siRNA for 48 h, respectively. We observed that the levels of STC-1 mRNA and secreted protein were decreased by STC-1 siRNA overexpression in the Hs578T and MDA-MB-231 TNBC cells. The levels of STC-1 mRNA expression were decreased to 0.58±0.07-fold and 0.39±0.06-fold of the control level in the STC-1 siRNA overexpressed cells, respectively (Fig. 3B,  left) . under the same conditions, the levels of STC-1 secreted protein were decreased to 0.49±0.04-fold and 0.23±0.003-fold of the control level in the STC-1 siRNA overexpressed cells, respectively (Fig. 3B, right) . In addition, the invasiveness of TNBC cells was completely suppressed by STC-1 siRNA overexpression (Fig. 3C) . The rates of cell invasion by STC-1 silencing were decreased to 56.96 and 58.16% of the control Hs578T and MDA-MB-231 cells, respectively (Fig. 3C) . Based on these results, the levels of STC-1 expression were directly associated with the invasive ability of the TNBC cells. (Fig. 4A) and MDA-MB-231 (Fig. 4B ) TNBC cells. The phosphorylation of JNK and c-Jun reached a maximum level 15 min after STC-1 treatment in the Hs578T cells (Fig. 4A) . We also observed that the STC-1-induced phosphorylation of JNK and c-Jun was still activated after 60 min in the MDA-MB-231 cells (Fig. 4B) . The phosphorylation of ERK was activated by STC-1 in the Hs578T cells, whereas the phosphorylation of ERK was not activated by STC-1 in the MDA-MB-231 cells (Fig. 4A and B) . The phosphorylation of p38 did not change in response to STC-1 treatment in both the Hs578T and MDA-MB-231 cells (Fig. 4A and B) . Therefore, we demonstrated that STC-1-induced JNK/c-Jun pathway activation may play an important role in the invasiveness of TNBC cells.
STC-1 activates the phosphorylation of JNK/c-

STC-1-induced cell invasion is suppressed by SP600125
in Hs578T TNBC cells. To ascertain the alteration of invasion-related genes such as MMPs by STC-1, we treated Hs578T TNBC cells with 50 ng/ml STC-1. As shown in Fig. 5A , STC-1 stimulated the levels of MMP-9 expression but not MMP-2 expression. The levels of MMP-9 mRNA expression were increased by 3.28±0.26-fold from the control level following STC-1 treatment (Fig. 5A) . under the same condition, STC-1 induced MMP-9 protein expression in the Hs578T TNBC cells (Fig. 5A) . Next, we pre-treated Hs578T TNBC cells with SP600125 for 1 h and then the cells were treated with 50 ng/ml STC-1. As expected, we observed that SP600125 completely suppressed STC-1-induced JNK phosphorylation in the Hs578T TNBC cells (Fig. 5B) . STC-1-induced MMP-9 mRNA expression was decreased to 0.67±0.02-fold of the control level by SP600125 (Fig. 5B) . Furthermore, we investigated whether the JNK/c-Jun signaling pathway is associated with STC-1-induced cell invasion in the Hs578T TNBC cells. The induction of cell invasiveness by STC-1 was also significantly decreased by SP600125 (Fig. 5C ). Based on these results, we demonstrated that JNK/c-Jun signaling activation by STC-1 triggers cell invasion through upregulation of MMP-9.
Discussion
STC-1 is highly expressed in a variety of cancers and has prognostic significance in colorectal and gastric cancers (15, 29) . Abnormal STC-1 expression is associated with poor prognosis in colorectal, esophageal, and gastric cancer patients (15, 29, 30) . However, to date, the clinical significance of STC-1 expression in breast cancer has not been well established. In this study, we investigated the correlation between STC-1 expression and survival of basal-type breast cancer patients as well as the regulatory mechanism of STC-1 in cell invasion. Consistent with previous reports, our results showed that high expression of STC-1 directly influences relapse-free and overall survival of basal-type breast cancer patients. However, the level of STC-1 expression had no relevance in regards to the survival of luminal-and HER2-type breast cancer patients (data not shown). Therefore, we demonstrated that the STC-1 expression level may be a promising prognostic marker in basal-type breast cancer patients.
STC-1 is involved with various biological events such as cell proliferation, migration, invasion, apoptosis, and inflammation in colon, gastric, and cervical cancer (14, 16, 31, 32) . In a recent study, we reported that the motility of TNBC cells such as invasion and migration was higher than these abilities in non-TNBC cells through TGF-β1 and -β2 expression (33) .
Here, we also observed that the levels of STC-1 mRNA and protein expression were significantly increased in the TNBC cells compared with these levels in the non-TNBC cells. Furthermore, our results showed that the invasiveness of TNBC cells was significantly increased by recombinant human STC-1 treatment. In contrast, STC-1 siRNA overexpression suppressed the invasiveness of the TNBC cells. Based on these reports, we demonstrated that STC-1 expression was directly associated with cell invasion in a variety of tumor cells including breast cancer cells. Abnormal activities of intracellular signaling molecules such as mitogen-activated protein kinases (MAPKs) in response to extracellular stimuli regulate a variety of cellular activities including cell proliferation, invasion, and transformation (34) . Activated MAPKs phosphorylate various substrate proteins including transcription factors such as c-Jun, ATF2, and p53 (34, 35) . Activation of the JNK/c-Jun signaling pathway is involved with cell invasion and metastasis in ovarian and glioma cancer (27, 28) . Heterotrimeric G protein, G12, also enhanced cell invasion through the activation of JNK in breast cancer cells (25) . Consistent with these reports, we found that STC-1 activated the phosphorylation of JNK and c-Jun in the TNBC cells. In addition, STC-1-induced cell invasion was completely suppressed by a specific JNK inhibitor, SP600125. Therefore, we demonstrated that the STC-1-induced cell invasion was regulated through the JNK/c-Jun-dependent signaling pathway in the TNBC cells.
The aim of this study was to investigate the clinical significance of STC-1 and the regulatory mechanism of STC-1-induced TNBC cell invasion. Aberrant STC-1 expression was associated with poor prognosis in basal-type breast cancer patients. The levels of STC-1 expression and the cell invasiveness were significantly increase in the TNBC cells when compared with that noted in the non-TNBC cells. On the other hand, cell invasiveness of TNBC was decreased by STC-1 siRNA overexpression. Furthermore, STC-1 induced the phosphorylation of JNK and c-Jun in the Hs578T and MDA-MB-231 TNBC cells and then augmented the invasive capacity of the TNBC cells. STC-1-induced cell invasion was suppressed by SP600125 in the TNBC cells. As shown in Fig. 6 , we demonstrated that STC-1 enhances the levels of MMP-9 expression through the JNK/c-Jun-dependent signaling pathway and then triggers cell invasion. Thus, we suggest that STC-1 may be a promising therapeutic target for the treatment of patients with TNBC tumors.
